Skip to main content

Advertisement

SpringerLink
Log in

Compliance, adherence, and the treatment of multiple sclerosis

  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

With the availability of disease-modifying, immunomodulatory therapies (DMT) for multiple sclerosis (MS) and the first long-term studies, it became obvious that problems of compliance to complex treatment regimens under chronic conditions would also apply to these approaches. In a selective overview, problems and findings of adherence research are depicted. Based on a discussion of basic concepts, issues of operationally defining and measuring adherence are outlined. Descriptive findings on adherence to DMTs and empirical predictors of nonadherence are then discussed. Referring to theoretical models of treatment motivation, selected problems (e. g., indication) and strategies of promoting adherence are described. Finally, implications of modern concepts of the patient-therapist relationship for the issue of patient adherence are considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Becker MH (1974) The health-beliefmodel and personal health behavior.Charles B. Slack, Thorofare

  2. Berger BA, Hudmon KS, Liang H(2004) Predicting treatment discontinuationamong patients with multiplesclerosis: Application of the transtheoreticalmodel of change. J Am PharmAssoc 44:445–454

    Article  Google Scholar 

  3. Berger BA, Liang H, Hudmon KS(2005) Evaluation of software-basedtelephone counseling to enhancemedication persistency among patientswith multiple sclerosis. J AmPharm Assoc 45:466–472

    Article  Google Scholar 

  4. Cramer JA, Roy A, Burrell A, FairchildCJ, Fuldeore MJ, Ollendorf DA, WongPK (2008) Medication compliance andadherence. Value in Health 11:44–47

    PubMed  Google Scholar 

  5. DiMatteo MR (2004) Social supportand patient adherence to medicaltreatment: A meta-analysis. HealthPsychol 23:207–217

    Google Scholar 

  6. DiMatteo MR (2004) Variations inpatients’ adherence to medical recommendations:A quantitative reviewof 50 years of research. Med Care 42:200–209

    Article  PubMed  Google Scholar 

  7. Drieschner KH, Lammers SMM, vander Staak CPF (2004) Treatment motivation:An attempt for clarification ofan ambiguous concept. Clin PsycholRev 23:1115–1137

    Article  Google Scholar 

  8. Fraser C, Morgante L, Hadjimichael O,Vollmer T (2004) A prospective studyof adherence to glatiramer acetate inindivuals with multiple sclerosis.J Neurosc Nurs 36:120–129

    Article  Google Scholar 

  9. Haas J, Firzlaff M (2005) Twenty-fourmonth comparison of immunomodulatorytreatments – a retrospectiveopen label study in 308 RRMS patientstreated with beta interferons or glatirameractetate. Eur J Neurol 12:425–431

    Article  PubMed  CAS  Google Scholar 

  10. Heesen C, Berger B, Hamann J, KasperJ (2006) Empowerment, Adhärenz,evidenzbasierte Patienteninformationund partizipative Entscheidungsfindungbei MS – Schlagworte oderWegweiser? Neurol Rehabil 12:232–238

    Google Scholar 

  11. Kanfer FH, Reinecker H, Schmelzer D(1996) Selbstmanagementtherapie (2nded.) Springer, Berlin

  12. Kern S, Reichmann H, Ziemssen T(2008) Therapieadhärenz in der neurologischenPraxis. Nervenarzt 79:877–890

    Article  PubMed  CAS  Google Scholar 

  13. Leventhal H, Meyer D, Nerenz D (1980)The common sense representation ofillness danger. In: Rachman S (ed)Contributions to medical psychology(vol. 2). Pergamon, New York, pp 7–30

  14. Meichenbaum D, Turk DC (1987)Facilitating treatment adherence: Apractitioner’s guidebook. Plenum, NewYork

  15. Milanese C, LaMantia L, Palombo R,et al (2003) A post-marketing study oninterferon β 1b and 1a treatment inrelapse-remittting multiple sclerosis:Different response in drop-outs andtreated patients. J Neurol NeurosurgPsychiatry 74:1689–1692

    Article  CAS  Google Scholar 

  16. Miller WR, Rollnick S (1991) Motivationalinterviewing: Preparing peopleto change addictive behavior. Guilford,New York

  17. Mohr DC, Boudewyn AC, Likosky W,Levine E, Goodkin DE (2001) Injectablemedication for the treatment ofmultiple sclerosis: The influence ofself-efficacy expectations and injectionanxiety on adherence and ability toself-inject. Ann Behav Med 23:125–132

    Article  PubMed  CAS  Google Scholar 

  18. O’Rourke KET, Hutchinson M (2005)Stopping beta-interferon therapy inmultiple sclerosis: An analysis of stoppingpatterns. Mult Scler 11:46–50

    Article  PubMed  Google Scholar 

  19. Petermann F, Mühlig S (1998) Grundlagenund Möglichkeiten der Compliance-Verbesserung. In: Petermann F(ed) Compliance und Selbstmanagement.Hogrefe, Göttingen, pp 73–102

  20. Portaccio E, Zipoli V, Siracusa G, SorbiS, Amato MP (2008) Long-term adherenceto interferon β therapy in relapse-remittingmultiple sclerosis. Eur Neurol59:131–135

    Article  PubMed  CAS  Google Scholar 

  21. Prohaska JO, DiClemente CC (1982)Transtheoretical psychotherapy:Toward a more integrative model ofchange. Psychother Theory Res Pract19:276–288

    Article  Google Scholar 

  22. Rio J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, Arévalo MJ,Nos C, Montalban X (2005) Factorsrelated with treatment adherence tointerferon β and glatiramer acetatetherapy in multiple sclerosis. MultScler 11:306–309

    CAS  Google Scholar 

  23. Ruggieri RM, Settipani N, Viviano L,Attanasio M, Giglia L, Almasio P, LaBella V, Piccoli F (2003) Long-terminterferon-beta treatment for multiplesclerosis. Neurol Sci 24:361–364

    Article  PubMed  CAS  Google Scholar 

  24. Schneider W (1990) Die Psychotherapiemotivation– Behandlungsvoraussetzungoder ein zu vernachlässigendesKonstrukt? In: Schneider W(ed), Indikationen zur Psychotherapie.Beltz, Weinheim, pp 183–201

  25. Schwarzer R (1992) Self-efficacy in theadoption and maintenance of healthbehaviors: Theoretical approaches anda new model. In: Schwarzer R (ed) Self-efficacy:Thought control of action.Hemisphere, Washington, pp 217–242

  26. Schwarzer R, Luszczynska A (2005)Compliance als universelles Problemdes Gesundheitsverhaltens. In:Schwarzer R (ed) Gesundheitspsychologie(Enzyklopädie der Psychologie,Vol. C/X/1). Hogrefe, Göttingen,pp 585–601

  27. Schwartz CE, Coulthard-Marris L,Zeng Q, Retzlaff P (1996) Measuringself-efficacy in people with multiplesclerosis: A validation study. Arch PhysMed Rehab 77:394–398

    Article  CAS  Google Scholar 

  28. Tremlett HL, Oger J (2003) Interruptedtherapy: Stopping and switching of theß-interferons prescribed for MS. Neurol61:551–554

    Google Scholar 

  29. Turner AP, Kivlahan DR, Sloan AP,Haselkorn JK (2007) Predicting ongoingadherence to disease modifyingtherapies in multiple sclerosis: Utilityof the Health Beliefs Model. Mult Scler13:1146–1152

    Article  PubMed  CAS  Google Scholar 

  30. World Health Organization (2003)Adherence to long-term therapies:Evidence of action. WHO, Geneva

Download references

Author information

Authors and Affiliations

  1. Medizinische Fakultät der Universität Rostock, Klinik und Poliklinik für Psychosomatik und Psychotherapeutische Medizin, Gehlsheimer Str. 20, 18147, Rostock, Germany

    Thomas Klauer

  2. Medizinische Fakultät der Universität Rostock, Klinik und Poliklinik für Neurologie, Gehlsheimer Str. 20, 18147, Rostock, Germany

    Uwe K. Zettl

Authors
  1. Thomas Klauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uwe K. Zettl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Klauer.

Additional information

Conflict of interest The authors have no conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klauer, T., Zettl, U.K. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 255 (Suppl 6), 87–92 (2008). https://doi.org/10.1007/s00415-008-6016-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-6016-8

Key words

Search

Navigation